PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What is pembrolizumab (Keytruda) for treating small-cell lung cancer (SCLC)?

ANSWER

This checkpoint inhibitor drug works on a certain type of SCLC called PD-L1-positive. Your doctor will test to see if you fall into this group.

SOURCES:

The Oncologist: “The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.”

American Cancer Society: “Small Cell Lung Cancer Treatment,” “What Is Immunotherapy?”

Meaghan L. Khan, MD, oncologist, Baylor Scott & White Healthcare.

Antonio Giordano, MD, PhD, director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University; professor of pathology, University of Sienna, Italy.

Scott Antonia, MD, PhD, chair, department of thoracic oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; professor, oncologic Sciences, University of South Florida College of Medicine, Tampa, FL.

NIH: “FAQ: ClinicalTrials.gov - Clinical Trial Phases.”

National Comprehensive Cancer Network: “About NCCN.”

Merck: “Frequently Asked Questions about pembrolizumab Expanded Access Program.”

Clinical Trials.gov: “SC16LD6.5 in Recurrent Small Cell Lung Cancer.”

OncoMed Pharmaceuticals: “Development Pipeline.”

Clinical Cancer Research: “Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency.”

Abstract presented at the 2016 ASCO Annual Meeting: “Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).”

Reviewed by Laura J. Martin on August 22, 2019

SOURCES:

The Oncologist: “The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.”

American Cancer Society: “Small Cell Lung Cancer Treatment,” “What Is Immunotherapy?”

Meaghan L. Khan, MD, oncologist, Baylor Scott & White Healthcare.

Antonio Giordano, MD, PhD, director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University; professor of pathology, University of Sienna, Italy.

Scott Antonia, MD, PhD, chair, department of thoracic oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; professor, oncologic Sciences, University of South Florida College of Medicine, Tampa, FL.

NIH: “FAQ: ClinicalTrials.gov - Clinical Trial Phases.”

National Comprehensive Cancer Network: “About NCCN.”

Merck: “Frequently Asked Questions about pembrolizumab Expanded Access Program.”

Clinical Trials.gov: “SC16LD6.5 in Recurrent Small Cell Lung Cancer.”

OncoMed Pharmaceuticals: “Development Pipeline.”

Clinical Cancer Research: “Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency.”

Abstract presented at the 2016 ASCO Annual Meeting: “Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).”

Reviewed by Laura J. Martin on August 22, 2019

NEXT QUESTION:

What is rovalpituzumab tesirine for treating small-cell lung cancer (SCLC)?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: